The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) is a technically-focused organization of pharmaceutical and biotechnology companies with a mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators and the broader R&D community.
IQ provides a sustained forum for the exchange of ideas within and across technical disciplines in these industries. The Consortium is leading initiatives in the areas of chemistry, manufacturing and control; preclinical safety; drug metabolism; clinical pharmacology; quality; and the reduction, refinement, and replacement of animal testing. As part of these initiatives, which are managed by Leadership Groups and Working Groups, members lead and participate in collaborative research, industry surveys and benchmarking exercises.
IQ is also partnering with governmental bodies, other trade groups, and academic researchers. Through publications, scientific conferences, workshops and roundtables, the Consortium shares the results of its work and facilitates constructive scientific exchange.
Board of Directors, Leadership Groups and Working Groups
The IQ Board of Directors is responsible for strategic oversight of the Consortium’s portfolio. The Board has representation from all member companies, and is the Consortium's primary decision-making body. Acting on the recommendations of Consortium committees and of its own initiative, it establishes objectives, policies and plans of action. Whenever possible, the Board operates on a consensus basis. The Consortium’s Planning Committee and Communications Committee, elected subgroups of Board members, provide guidance on Consortium matters between Board sessions.
Leadership Groups are standing, discipline-specific forums that allow experts in major areas of pharmaceutical science to discuss and craft strategies to address key challenges. They liaise regularly with the Board of Directors and form and oversee project-specific working groups. Leadership Groups are also responsible for encouraging collaboration within the organization, particularly across disciplines.
Working Groups are project-based expert groups which are formed to address specific, critical, and timely issues in drug development such as drug-drug interaction, pediatric drug development, contract manufacturing and phase-appropriate good manufacturing practices, among others. They are sponsored and overseen by Leadership Groups, with membership determined by the needs of a project. Working Groups are dissolved upon completion of their projects.
Participation in the Board of Directors and Leadership Groups is limited to individuals from IQ member companies. However, experts from outside IQ member companies, such as academic researchers and regulatory authorities, are periodically invited to participate in Working Groups.